Historique de carrière de Ofir Moreno
Anciens postes connus de Ofir Moreno
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MEI PHARMA, INC. | Directeur Technique/Scientifique/R&D | 01/07/2012 | 01/07/2019 |
| Corporate Officer/Principal | 01/07/2019 | 01/07/2022 | |
| DENDREON CORPORATION | Corporate Officer/Principal | 01/08/2003 | 01/11/2007 |
Formation de Ofir Moreno
| Cornell University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEI PHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
- Bourse
- Insiders
- Ofir Moreno
- Expérience
